Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
04:05pm, Monday, 16'th Mar 2026
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Sees Large Growth in Short Interest
03:50am, Sunday, 15'th Mar 2026
Atara Biotherapeutics, Inc. (NASDAQ: ATRA - Get Free Report) saw a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 330,524 share
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
08:05am, Thursday, 12'th Mar 2026
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
08:05am, Tuesday, 03'rd Mar 2026
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo
Atara Biotherapeutics Provides a Business Update
08:00am, Monday, 23'rd Feb 2026
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
06:56pm, Thursday, 12'th Feb 2026
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advise
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
01:33pm, Tuesday, 03'rd Feb 2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA). Such invest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
10:00am, Thursday, 29'th Jan 2026
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advi
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Short Interest Update
01:40am, Wednesday, 28'th Jan 2026
Atara Biotherapeutics, Inc. (NASDAQ: ATRA - Get Free Report) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,016,616 share
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
12:47pm, Tuesday, 27'th Jan 2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA). Such invest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
10:00am, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
01:13pm, Tuesday, 20'th Jan 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA). Such investor
Innovation Ltd Panacea Sells 80,554 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock
04:34am, Friday, 16'th Jan 2026
Atara Biotherapeutics, Inc. (NASDAQ: ATRA - Get Free Report) major shareholder Innovation Ltd Panacea sold 80,554 shares of the business's stock in a transaction on Monday, January 12th. The stock was
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
08:00am, Monday, 12'th Jan 2026
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
09:00am, Wednesday, 12'th Nov 2025
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo
